Connexios Life Sciences

Connexios Life Sciences is a Bangalore-based biotechnology company specializing in the discovery and development of novel small molecule therapies for metabolic diseases, including Type 2 diabetes and NASH. The company utilizes a proprietary Network Biology platform to understand the complex cellular networks underlying disease states and identify multi-target or highly specific intervention points. Their lead program, an 11β-HSD1 inhibitor, was notably partnered with Boehringer Ingelheim for global development. Connexios focuses on translational research to bridge the gap between early-stage discovery and clinical proof-of-concept. In 2021, the company was acquired by STEER Life to integrate its drug discovery capabilities with advanced pharmaceutical processing technologies.